EvoNext Holdings Ltd, previously Evolva Holding Ltd, is a Switzerland-based Company operating as a researcher for biotechnology. The Company develops and commercializes nature-based ingredients. The ingredients, produced by the Company, can be employed in, but not limited to, flavorings fragrancies, health ingredients, health protection and other various sectors. The objectives of the Company are as follows: develop technology platforms - combines biology with technology to produce nature-based ingredients; provide technology services- provides tailored services to clients across industries. The Company is focused on developing and increasing the return and effectiveness of the production of numerous ingredients within their portfolio.

Employees

Sector

Biotechnology & Medical Research

More about the company

11-02	EvoNext Holdings Enters Deal to Merge with Ascend Sport Technology	MT
10-12	Ascend Sport Technology to List on SIX Swiss Exchange via EvoNext Merger	MT

Market Cap	16.8M 20.51M 18.31M 15.28M 28.66M 1.94B 29.23M 201M 80.9M 1.02B 76.97M 75.33M 3.24B	P/E 2024	6.22x	P/E 2025	-8.95x
Enterprise Value	10.9M 13.3M 11.88M 9.91M 18.59M 1.26B 18.96M 130M 52.47M 665M 49.92M 48.86M 2.1B	EV / Sales 2024	-	EV / Sales 2025	-
Free-Float	62.03%	Yield 2024 *	-	Yield 2025	-

11-02	EvoNext Holdings Enters Deal to Merge with Ascend Sport Technology	MT
10-12	Ascend Sport Technology to List on SIX Swiss Exchange via EvoNext Merger	MT
10-11	Ascend Sport Technology AG signed a binding transaction agreement to acquire EvoNext Holdings SA for approximately CHF 500 million in a reverse merger transaction.	CI
09-30	EvoNext Holdings SA Reports Earnings Results for the Half Year Ended June 30, 2026	CI
09-30	EvoNext Holdings' H1 Net Loss Widens; Financial Income Up	MT
08-18	Evonext Holds Talks to Take Ascend Sport Public	CI
08-17	EvoNext in Advanced Negotiations with Ascend Sport Technology for Reverse Merger	MT
08-17	Switzerland's Ascend Sport Technology Mulls Reverse Merger With EvoNext	MT
08-17	Switzerland's Ascend Sport Technology Mulls Reverse Merger With EvoNext	MT
04-29	EvoNext Holdings SA Reports Earnings Results for the Full Year Ended December 31, 2025	CI
25-08-20	EvoNext Holdings SA Reports Earnings Results for the Half Year Ended June 30, 2025	CI
25-07-25	Evolva Shareholders OK Proposed Renaming to EvoNext	MT
25-07-25	Evolva Holding SA has Changed its Name to EvoNext Holdings SA	CI

11-02	EvoNext Holdings SA and Ascend Sport Technology AG sign merger agreement	EQ
10-12	EvoNext Holdings SA and Ascend Sport Technology AG sign transaction agreement	EQ
09-30	EvoNext Holdings SA publishes half-year report 2026	EQ
08-17	EvoNext Holdings SA confirms advanced discussions on a reverse merger with Ascend Sport Technology AG	EQ
05-20	EvoNext : Minutes of Annual General Meeting 2026	PU

11-02	EvoNext: fusion avec Ascend Sport Technology actée
11-02	Evonext und Ascend unterzeichnen Fusionsvertrag
10-12	Ascend Sport Technology sbarcherà in borsa
10-12	Sporttech-Firma Ascend will durch Fusion mit EvoNext an Schweizer Börse
10-12	Evonext und Ascend Sport einigen sich auf Fusion

ARPIDA Stock Swiss Exchange

Stocks

ARPN

Biotechnology & Medical Research

Valuation: ARPIDA

Latest news: ARPIDA

Analysts' recommendations: ARPIDA

Press Releases: ARPIDA

News in other languages: ARPIDA

Managers and Directors: ARPIDA

Other Biotechnology & Medical Research

Financials

Company Profile

Director	Title	Age	Since
Francesco Defila BRD	Director/Board Member	-	2025-03-26
Gianluca Ferrari CHM	Chairman	-	2025-03-26

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
WUXI APPTEC CO., LTD.	-2.37%	-5.03%	+39.49%	+62.39%	63.77B
ARGENX SE	-2.87%	+0.49%	+11.11%	+69.18%	56.37B
LONZA GROUP AG	+0.62%	+2.11%	+16.96%	+102.56%	54.62B
IQVIA HOLDINGS INC.	-3.33%	-5.54%	+19.39%	+35.69%	44.06B
BEONE MEDICINES AG	-2.45%	-2.59%	+16.36%	+98.45%	42.11B
REVOLUTION MEDICINES, INC.	-1.64%	+2.32%	+219.80%	+789.69%	41B
GENMAB A/S	-5.47%	+24.76%	+101.20%	+87.34%	34.92B
CELLTRION, INC.	+0.21%	+1.05%	+14.81%	+46.96%	32.82B
INSMED INCORPORATED	-2.90%	+17.12%	-42.35%	+337.07%	24.7B
Average	-2.24%	+6.84%	+44.09%	+181.04%	43.82B
Weighted average by Cap.	-2.16%	+4.83%	+44.63%	+163.55%

	2024	2025
Net sales	-	-
Net income	1.04M 1.27M 1.14M 950K 1.78M 121M 1.82M 12.47M 5.03M 63.66M 4.78M 4.68M 201M	-653K -797K -711K -594K -1.11M -75.42M -1.14M -7.8M -3.14M -39.81M -2.99M -2.93M -126M
Net Debt	-6.75M -8.24M -7.36M -6.14M -11.52M -780M -11.75M -80.66M -32.51M -412M -30.94M -30.28M -1.3B	-5.91M -7.21M -6.44M -5.37M -10.07M -682M -10.27M -70.54M -28.43M -360M -27.05M -26.48M -1.14B

End-of-day quote Swiss Exchange
- ^CHF	-